Chryseobacterium: Infections, Causes, and Treatment

Chryseobacterium is a genus of bacteria found widely in soil and water that occasionally causes serious infections in hospitalized and immunocompromised people. These infections are uncommon but clinically significant because the organism carries built-in resistance to many commonly used antibiotics, including carbapenems, which are often drugs of last resort. Most cases involve patients already in intensive care with indwelling devices or prolonged antibiotic exposure, though rare infections in otherwise healthy individuals have been documented.

What Chryseobacterium Is and Where It Lives

Chryseobacterium belongs to the family Flavobacteriaceae and includes dozens of species, most of which are harmless environmental organisms. The genus was formally defined in 1994, replacing the older classification under Flavobacterium. Of the many species, a handful show up repeatedly in clinical settings. C. indologenes is by far the most common cause of human infection, followed by C. gleum. A three-year clinical study found that C. indologenes accounted for 18 out of 20 Chryseobacterium isolates, with C. gleum making up the remaining two.¹ Other species like C. arthrosphaerae appear in case reports but remain rare.

One important historical note: the species once called Chryseobacterium meningosepticum, responsible for severe neonatal meningitis outbreaks, was reclassified into its own genus, Elizabethkingia, in 2005 based on genetic analysis showing it was a distinct lineage from the rest of Chryseobacterium.² Older literature still uses the Chryseobacterium name for this organism, which can cause confusion when reading case reports from before the reclassification.

In the environment, Chryseobacterium species thrive in wet settings. In hospitals, the bacteria colonize water systems, sink drains, and plumbing fixtures. One investigation in an intensive care unit traced a cluster of C. indologenes cases to contaminated sinkholes and drainage water; removing the wash basins stopped new infections from occurring.³ A separate study in ICUs found C. indologenes and Elizabethkingia meningoseptica in environmental samples from under-utilized taps, suggesting that stagnant water in seldom-used faucets creates a breeding ground.⁴ In a more recent investigation of C. arthrosphaerae infections at an Italian hospital, the bacterium was found in a tap used to wash patients; installing a point-of-use water filter eliminated the organism from follow-up samples.⁵

Who Gets Infected

Chryseobacterium infections are overwhelmingly healthcare-associated. The typical patient has serious underlying illness and is receiving intensive care. In a 20-year study at a single university hospital, every patient who developed C. indologenes bloodstream infection was hospitalized at the time, and all received ICU-level care.⁶ Recognized risk factors include being a newborn or having a weakened immune system, staying in an ICU for more than three weeks, exposure to broad-spectrum antibiotics, and the use of indwelling devices such as central venous catheters and mechanical ventilators.⁷

In one retrospective series of 16 patients with C. indologenes bloodstream infection, all had underlying diseases, and the majority had undergone invasive procedures. Other common associated conditions included immunosuppression, low white blood cell counts, and prolonged antibiotic use.⁸ Cancer is a recurring theme: one documented case involved a 59-year-old man with metastatic squamous cell carcinoma of the lung who developed C. indologenes bloodstream infection.⁹

That said, healthy people are not entirely exempt. A case report described severe sepsis from C. indologenes in a fit adventure traveler with no underlying conditions, demonstrating that the bacterium can cause life-threatening disease outside the hospital, albeit rarely.¹⁰

Types of Infections

Chryseobacterium can cause a range of infections. Bloodstream infection (bacteremia) and pneumonia are the most frequently reported. Other documented sites include the urinary tract, peritoneum, pleural space, meninges, and soft tissues, as well as catheter-related infections and ocular infections.¹¹ Endocarditis and cellulitis have also been described.¹²

Ventilator-associated pneumonia (VAP) deserves special mention because it places C. indologenes at the intersection of two vulnerabilities: a contaminated hospital water supply and a mechanically ventilated patient. The first reported case of VAP caused by C. indologenes dates to 1993, and small outbreaks of lower respiratory tract infection have been reported among elderly ICU patients since then.¹² A trauma ICU case further confirmed C. indologenes as a cause of VAP in critically ill patients.¹³

In the largest published analysis of C. indologenes infections, covering 215 cases, in-hospital mortality differed sharply by infection type. Among patients with bloodstream infection, roughly two-thirds died in the hospital. Among those with pneumonia, the in-hospital mortality was about a third. In the bloodstream infection group, stroke and cancer were the most common underlying conditions.¹⁴

Neonatal Vulnerability

Newborns in intensive care are at particular risk for Chryseobacterium-related infections, a pattern that dates back decades. Much of the older neonatal literature involves Chryseobacterium meningosepticum, now reclassified as Elizabethkingia meningoseptica, but the underlying dynamic is similar: vulnerable babies, contaminated hospital water, and limited antibiotic options.

In one NICU outbreak, four newborns developed bloodstream infection over an 11-day period. The first neonate died before the culture result was available. When the organism was identified, the remaining three were switched to a combination of ciprofloxacin, rifampicin, and vancomycin, and all three survived.¹⁵ A longer outbreak at another hospital spanned nearly two years and involved eight neonates, of whom two were infected (one with pneumonia, one with sepsis and meningitis) and six were colonized. Investigation traced the source to contaminated water taps in the unit.¹⁶ These cases illustrate how hospital plumbing can serve as a persistent reservoir that threatens the most fragile patients.

Why These Infections Are Hard to Treat

The central challenge with Chryseobacterium is its built-in resistance to many antibiotics. Unlike acquired resistance, which bacteria pick up over time from selective pressure, Chryseobacterium species produce a chromosomally encoded metallo-beta-lactamase enzyme that destroys beta-lactam antibiotics, including carbapenems.¹⁷ This means the organism is resistant before it ever encounters a drug. Several variants of this enzyme (designated IND-1, IND-2, and others) have been characterized, and they share a broad ability to break down carbapenems and other beta-lactams.¹⁸ The earliest characterized enzyme, IND-1, shares only about 43% sequence identity with a related enzyme from the former C. meningosepticum, suggesting a diverse and long-standing family of resistance genes across the genus.¹⁹

Beyond this inherent resistance, there is evidence that Chryseobacterium species can also share resistance genes with other bacteria. One study identified a mobile genetic element in C. indoltheticum that carries a beta-lactamase gene and was shown to transfer to E. coli in laboratory mating experiments.²⁰ This raises the concern that Chryseobacterium could act as a reservoir of resistance genes that spread to more common pathogens.

In addition to beta-lactamase production, genomic studies have identified virulence-related genes in Chryseobacterium species involved in adherence, biofilm formation, and cellular stability.²¹ Biochemical profiling of at least one environmental isolate has demonstrated protease, lipase, and gelatinase activity, which could contribute to tissue damage during infection.²²

Antibiotic Options That Work

Because so many standard antibiotics fail against Chryseobacterium, choosing the right drug is critical. The same 215-case analysis mentioned earlier found that giving an effective antibiotic significantly improved 14-day survival in patients with bloodstream infection.¹⁴ But “effective” is a short list.

A global surveillance study covering isolates from 1997 to 2001 found that newer fluoroquinolones (like levofloxacin and gatifloxacin) were the most active agents, with about 98% of isolates susceptible, followed by rifampin at roughly 86%. Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazobactam also showed reasonable activity. Vancomycin performed poorly.²³

More recent data tell a somewhat less optimistic story, possibly reflecting resistance trends over time. A study comparing C. gleum and C. indologenes found that minocycline was the most active drug overall, with about 73% of isolates susceptible, followed by trimethoprim-sulfamethoxazole at roughly 48%, tigecycline at about 34%, and levofloxacin at about 33%. Interestingly, C. gleum was significantly more susceptible than C. indologenes to several drugs, including piperacillin, piperacillin-tazobactam, ceftazidime, tigecycline, and levofloxacin.²⁴ The three-year clinical study found rifampicin susceptibility at 75% and piperacillin-tazobactam at 45%.¹ Strains isolated from cystic fibrosis patients showed activity only for trimethoprim-sulfamethoxazole and quinolones, with broad resistance to everything else.²⁵

Whether combination therapy improves outcomes compared to a single drug remains unclear. A Singapore retrospective review looking at bloodstream infections from Chryseobacterium (and related organisms) found too few cases of dual therapy to draw conclusions about whether it helped.²⁶ In practice, clinicians often rely on fluoroquinolones, trimethoprim-sulfamethoxazole, or minocycline, guided by individual susceptibility testing.

Diagnosis Is Not Straightforward

Identifying Chryseobacterium to the species level can be tricky, which matters because susceptibility patterns differ between species. The main diagnostic tools used in hospital labs, which rely on mass spectrometry to match bacterial protein profiles against reference databases, have gaps. One comparison of two major systems found that while one correctly identified all C. indologenes and C. gleum isolates, the other correctly identified 99% of C. indologenes but only about 3% of C. gleum. Neither system could identify uncommon Chryseobacterium species at all, giving an overall species-level accuracy of about 61% and 91%, respectively.²⁷

A separate evaluation found low overall agreement among different identification methods for C. indologenes and Elizabethkingia meningoseptica, even when using mass spectrometry, with results showing low confidence levels.²⁸ The practical consequence is that some Chryseobacterium infections are likely misidentified or reported under the wrong species name, and database updates for the diagnostic platforms remain an ongoing need.

Prognosis and What Predicts a Worse Outcome

Mortality from Chryseobacterium bloodstream infection varies considerably across published series, probably reflecting differences in patient populations and how quickly appropriate antibiotics are started. The 215-case analysis reported in-hospital mortality around 64% for bacteremia patients.¹⁴ The 20-year single-center study recorded much lower figures: 14-day mortality of about 8% and 28-day mortality of about 17%, with all patients having underlying disease.⁶

Several factors have been linked to worse outcomes. Low blood albumin (below 2.5 g/dL) at the time of infection, elevated heart rate, and having a central venous catheter in place were associated with death in one analysis.²⁹ Another found that longer duration of fever and higher markers of inflammation at the time of bloodstream infection predicted mortality.³⁰ These markers broadly point to sicker patients with more intense infections doing worse, which is not surprising, but they can help clinicians identify patients who need the most aggressive early management.

Chryseobacterium Beyond Human Disease

For all the trouble it causes in hospitals, Chryseobacterium’s natural habitat is soil and water, where many species play ecologically useful roles. Genomic analysis across the genus has found that genes involved in phosphorus and zinc cycling are present in essentially all Chryseobacterium species, while genes for nitrogen and sulfur cycling tend to appear specifically in soil-dwelling strains.³¹ Some species actively promote plant growth. One strain of C. gleum isolated from salt-stressed soil was shown to help wheat tolerate salinity while simultaneously breaking down poultry feather waste into a usable biostimulant.³²

That feather-degrading ability points to another area of interest: industrial biotechnology. Chryseobacterium species produce powerful keratinase enzymes that can break down keratin, the tough structural protein in feathers, hair, and wool. One isolate from a poultry waste site in India degraded nearly 99% of chicken feathers within 30 hours.³³ Given that millions of tons of feather waste are generated by poultry processing worldwide, biological degradation by Chryseobacterium strains could offer an alternative to landfilling or incineration.

Chryseobacterium in Aquaculture

Some Chryseobacterium species cause disease in fish, adding an animal health dimension. C. balustinum has been identified as an opportunistic pathogen in farmed rainbow trout, causing moderate disease and prompting study of its susceptibility to common aquaculture antibiotics.³⁴ The concern is not so much direct transmission from fish to humans as the broader ecological picture: antibiotic-resistant Chryseobacterium in aquaculture water systems carrying transferable resistance elements that could move to other bacterial species. The demonstration that at least one Chryseobacterium species can pass a beta-lactamase gene to E. coli in the lab makes that scenario more than hypothetical.²⁰ Aquaculture environments, with their warm, nutrient-rich water and frequent antibiotic use, are exactly the kind of setting where resistance genes circulate most freely.